Navigation Links
Celecoxib may be effective in preventing non-melanoma skin cancers
Date:11/29/2010

Celecoxib may help prevent nonmelanoma skin cancers in patients with extensive actinic keratosis, which is often a precursor to these cancers, according to a randomized clinical trial published online November 29 in The Journal of the National Cancer Institute.

Nonmelanoma skin cancersincluding cutaneous squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs)are among the most common cancers in the United States. The incidence of these malignancies is rising and is beginning to occur more frequently in young adults. Exposure to UV radiation is believed to be one of the main causes. Existing methods of protecting against UV light, namely sunscreens, have only been modestly effective at reducing these cancers' incidence, so researchers have begun looking for other ways to prevent them. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits the enzyme cyclooxygenase 2, believed to be involved in the development of UV-induced nonmelanoma skin cancers.

To determine whether celecoxib reduces the incidence of new actinic keratosis, Craig A. Elmets, M.D., of the University of Alabama at Birmingham, and colleagues, conducted a double-blind, placebo-controlled randomized trial with 240 people with actinic keratoses, or precancerous skin lesions. They looked at the number of new lesions after 3, 6, and 9 months of therapy and at 2 months following the completion of therapy.

The researchers found that the number of new precancerous lesions in the group of people taking celecoxib and those taking the placebo was the same. However, by the end of the trial, those taking celecoxib had a statistically significant fewer number of nonmelanoma skin cancers compared with those in the placebo group.

The researchers write, "The findings of this study, which showed that the celecoxib-treated individuals developed fewer nonmelanoma skin cancers than placebo-treated individuals, suggest that cyclooxygenase inhibitors may provide an additional benefit to sunscreens in the prevention of nonmelanoma skin cancers."

The finding that celecoxib did not reduce the number of precancerous lesions was inconsistent with animal studies showing that celecoxib reduced both precancerous lesions and nonmelanoma skin cancers. However, the drug's efficacy against later stages of tumor development was consistent with findings of trials of celecoxib for colorectal adenoma.

The FDA terminated the study early, after preliminary findings from a concurrent trial of another cyclooxygenase 2 inhibitor showing an increased risk of cardiovascular adverse events. The fact that no adverse cardiovascular events were found with this trial could be because the study participants were only taking it for 9 months, the researchers point out. Another trial showed that adverse events occurring only after 1 year of rofecoxib, a cyclooxygenase-2 inhibitor.

In an accompanying editorial, Frank L. Meyskens Jr. M.D., and Christine E. McLaren, Ph.D., of the University of California, Irvine write that the fact that celecoxib was effective in reducing the number of nonmelanoma skin cancers but not the number of precancerous lesions may suggest that pathways of carcinogenesis differ between early- and late-stage tumor development.

The editorialists say future trials of celecoxib might try lowering the frequency of celecoxib administration, given the adverse cardiovascular events shown by other trials, or use a lower dosage in combination with other compounds with proven efficacy in colorectal adenoma.


'/>"/>

Contact: Kristine Crane
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Sporadic breast cancers start with ineffective DNA repair systems, Pitt researchers find
2. Hemostatic drug less effective than originally predicted
3. New Malaria Drug Proves Effective in Study of African Children
4. 5-year results show keyhole bowel cancer surgery is safe and effective
5. New lymphoma therapy may be more effective with fewer side effects
6. Diverse surgeons initiative effectively increases underrepresented minorities in academic surgery
7. Gene Mutations May Blunt Plavixs Effectiveness, Study Finds
8. Newer, more intense chemotherapy with less radiation not more effective against Hodgkins lymphoma
9. Parent-only treatment may be equally effective for children who are obese
10. Home Monitoring of Blood-Thinner Use Appears Effective
11. Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... MA (PRWEB) , ... January 17, 2017 , ... ... season, Au Bon Pain, an internationally recognized leader in the fast-casual category, announces ... items such as the Good Egg Breakfast Sandwich, Turkey Mash-Up Sandwich, Cranberry Crunch ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... California Southern ... Beazley has served on CalSouthern’s Board of Trustees and as a core faculty member, ... he has been a professor of psychology at Pepperdine University, where he earned his ...
(Date:1/16/2017)... Elk Grove Village, IL (PRWEB) , ... January ... ... protection and personal audio products, will demonstrate their groundbreaking GunSport•PRO® and EB15•LE® electronic ... Expo and Convention Center in Las Vegas, Booth #2809. The SHOT Show is ...
(Date:1/16/2017)... ... , ... Anybody who may be looking for a substance abuse rehabilitation program ... Recovery, a holistic treatment center for addiction located in Marne, MI. This video, which ... patients and staff that visited the 2016 Recovery Palooza support event in nearby Grand ...
(Date:1/16/2017)... ... 16, 2017 , ... As New York’s fastest growing ophthalmic ... to their medical staff, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief ... division of SightMD. Dr. Giamos will practice primarily out of SightMD’s Riverhead, Southampton, ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... According to a new market research report "Neural Network Software Market by Type ... Region - Global Forecast to 2021" published by MarketsandMarkets, the market to expand ... a Compound Annual Growth Rate (CAGR) of 33.2%. ... ... ...
(Date:1/17/2017)...  Market Research Future published a Half Cooked Research Report on ... reach USD 33.6 million during the period 2016 to 2022 from ... ... has been examined as a swiftly growing market and expected to ... endoscopy device in various regions.  The increasing growth in endoscopy procedures ...
(Date:1/17/2017)... Calif. and KANSAS CITY, ... Children,s Hospitals Neonatal Consortium (CHNC) has selected Velos ... their visionary data management and multicenter initiatives. ... organization comprised of 32 Neonatal Intensive Care Units ... America . The consortium provides a benchmark ...
Breaking Medicine Technology: